DX308 / DermaXon - LARVOL DELTA

Targeting retinoid acid metabolic pathway to improve neurobehavioral function after spinal cord injury (Neuroscience 2024) - "Our result indicated that application of DX308 during the acute/subacute stage improves morphological and functional outcomes after SCI. This study provides promising evidence that inhibiting CYP26 enzymes by DX308 to maintain higher levels of endogenous retinoic acid can mitigate the detrimental effects of SCI and enhance neurobehavioral recovery."

Late-breaking abstract • CNS Disorders • Pain • CYP26A1 • FAP • GFAP